The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)

Table 5 Economic model parameters

Disease type	Parameter	Hydrocele average estimate	Lymphedema average estimate	Sources
Acute	Average patient medical expenses per ADL episode	Country-specific (US$1.18^a)	Country-specific (US$1.18^a)	[8, 11, 44–48]
Chronic	Average patient medical expenses for chronic disease per year	Country-specific (US$0.70^ac)	Country-specific (US$1.05^ac)	[8, 11, 44–48]
Acute	Percentage of work hours lost per day during an ADL episode	75 %^b	75 %^b	[12, 14, 16, 87]
Chronic	Percentage of work hours lost due to chronic disease	15 %^b	19 %^b	[12, 43 , 45, 46]
Acute & chronic	Average wage per day (minimum of sources (Table 6))	Country-specific (US$1.50^a)	Country-specific (US$1.50^a)	[53–56]
Chronic	Work days per year	300^b,d	300^b,d

Based on [4], though updated where appropriate
^aWeighted average over all GPELF countries (based on the benefit cohort population size in each country) (Additional file 2: Table S2 and Table 6)
^bGlobal estimate indicates a standard rate or proportion was utilized for each GPELF country. This is primarily due to a lack of supporting country-specific data
^cChronic hydrocele and lymphedema patients are assumed to seek treatment on average two and three times a year respectively
^dAssume an average 6 day work week, 50 weeks of the year
Costs are expressed in US$ 2014 prices
ADL acute adenolymphangitis

ISSN: 2049-9957